Boardroom Alpha
Boardroom Alpha
HCA · Additional Proxy Materials (DEFA14A) · Filed March 13, 2026

Hca Healthcare Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 13, 2026
Ticker
HCA
Accession
0001193125-26-106153
Boardroom Alpha · Filing insights

HCA Healthcare supports its director slate and routine governance measures; opposes two shareholder-rights proposals.

About Hca Healthcare Inc
Market cap
$81.5B
1Y TSR
+9.5%
3Y TSR
+13.9%
Board grade
B+
Sector
Healthcare
CEO
Samuel N Hazen
Last annual meeting: Apr 23, 2026 · View full Hca Healthcare Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

 

Filed by the Registrant  

 

Filed by a party other than the Registrant  

 

Check the appropriate box:

 

 

 

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material Under Rule 240.14a-12

HCA Healthcare, Inc.

 

 

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

  No fee required.

  Fee paid previously with preliminary materials.

  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 
 


LOGO

Your Vote Counts! HCA HEALTHCARE, INC. 2026 Annual Meeting Vote by April 22, 2026 11:59 PM ET. For shares held in a Plan, vote by April 20, 2026 11:59 PM ET. HCA HEALTHCARE, INC. ATTN: CORPORATE SECRETARY ONE PARK PLAZA NASHVILLE, TN 37203 V86570-P42755 You invested in HCA HEALTHCARE, INC., and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on April 23, 2026. Get informed before you vote View the Notice and Proxy Statement and 2025 Annual Report online, OR you can receive a free paper or email copy of the material(s) by requesting prior to April 9, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Vote Virtually at the Meeting* Point your camera here and April 23, 2026 2:00 PM CDT vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/HCA2026 *Please check the meeting materials for any special requirements for meeting attendance.


LOGO

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Board Voting Items Recommends 1. Election of Directors Nominees: 1a. Thomas F. Frist III For 1b. Samuel N. Hazen For 1c. John W. Chidsey, III For 1d. Nancy-Ann DeParle For 1e. William R. Frist For 1f. Hugh F. Johnston For 1g. Michael W. Michelson For 1h. Wayne J. Riley, M.D. For 1i. Andrea B. Smith For 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year For ending December 31, 2026. 3. Advisory vote to approve named executive officer compensation. For 4. Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Against 5. Stockholder proposal, if properly presented at the meeting, regarding shareholders’ right to act by written consent. Against NOTE: In their discretion, the proxies are authorized to vote upon any other business that may properly come before the meeting or any postponement or adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Hca Healthcare Inc (HCA)

Reference

Frequently asked questions

When did Hca Healthcare Inc file this DEFA14A?
Hca Healthcare Inc (HCA) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 13, 2026. The accession number assigned by EDGAR is 0001193125-26-106153.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
HCA Healthcare supports its director slate and routine governance measures; opposes two shareholder-rights proposals. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Hca Healthcare Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Hca Healthcare Inc has filed under CIK 860730, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer